Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy.

McVicar CM, Hamilton R, Colhoun LM, Gardiner TA, Brines M, Cerami A, Stitt AW

Diabetes12 Sept 2011Cited by 98 (Europe PMC)

PMID21911748PMCIDPMC3198080DOI10.2337/db11-0026PepBankPUB-21911748

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In diabetic rats and nondiabetic controls, pHBSP or scrambled peptide treatment did not alter hematocrit.
In plain wordsIn rats, pHBSP did not change hematocrit, the share of red blood cells in the blood.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changeHematocrit
Study
Ratn = 24
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Adverse events · Whole body
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
pHBSP or scrambled peptide treatment did not alter hematocrit.
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174801
02AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rat retina, pHBSP significantly reduced the diabetes-related rise in Müller glial glial fibrillary acidic protein expression.
In plain wordsIn diabetic rats, pHBSP reduced a stress response of supporting cells in the retina compared with scrambled peptide.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseMüller glial GFAP expression
Study
Ratn = 12
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Neuroprotection · Eye
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
In the diabetic retina, Müller glial expression of glial fibrillary acidic protein was increased when compared with nondiabetic controls, but pHBSP significantly reduced this stress-related response (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174802
03AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rat retina, pHBSP attenuated some of the diabetes-related rises in CD11b+ microglia.
In plain wordsIn diabetic rats, pHBSP reduced some signs of immune cell activation in the retina.
Peptide
Cibinetide (ARA-290)
Outcome
MixedRetinal microglia (CD11b+) activation
Study
Ratn = 12
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Inflammation markers · Eye
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
CD11b+ microglia and proinflammatory cytokines were elevated in diabetic retina responses, and some of these responses were attenuated by pHBSP (P < 0.01-0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174803
04AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rat retina, pHBSP attenuated some of the diabetes-related rises in proinflammatory cytokines.
In plain wordsIn diabetic rats, pHBSP lowered some inflammatory signals in the retina.
Peptide
Cibinetide (ARA-290)
Outcome
MixedRetinal proinflammatory cytokines
Study
Ratn = 12
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Inflammation markers · Eye
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
CD11b+ microglia and proinflammatory cytokines were elevated in diabetic retina responses, and some of these responses were attenuated by pHBSP (P < 0.01-0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174804
05AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rat retina, pHBSP significantly reduced diabetes-linked DNA damage measured by 8-hydroxydeoxyguanosine and TUNEL positivity.
In plain wordsIn diabetic rats, pHBSP reduced DNA damage in the retina compared with scrambled peptide.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseDiabetes-linked retinal DNA damage
Study
Ratn = 12
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Neuroprotection · Eye
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
pHBSP significantly reduced diabetes-linked DNA damage as determined by 8-hydroxydeoxyguanosine and transferase-mediated dUTP nick-end labeling positivity
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174805
06AnimalAnimal study (in vivo)Efficacy outcome
In diabetic rat retina, pHBSP prevented acellular capillary formation.
In plain wordsIn diabetic rats, pHBSP prevented the loss of cells from small retinal blood vessels.
Peptide
Cibinetide (ARA-290)
Outcome
DecreaseAcellular capillary formation
Study
Ratn = 12
Streptozotocin-induced diabetic rat retina
Comparator
Scrambled peptide
Outcome group
Vision and retina · Eye
Studied dose
10 μg/kg per day · 1 monthAs given in this study (Rat).
Source sentences
Summary
and also prevented acellular capillary formation (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
After 6 months of streptozotocin-induced diabetes, rats (n = 12) and age-matched nondiabetic controls (n = 12) were evenly split into pHBSP and scrambled peptide groups and injected daily (10 μg/kg per day) for 1 month.
Report a problemFND-2191174806
07AnimalAnimal study (in vivo)Efficacy outcome
In oxygen-induced retinopathy, pHBSP had no effect on preretinal neovascularization at any dose.
In plain wordsIn an eye disease model, pHBSP did not change the growth of new retinal blood vessels at any dose.
Peptide
Cibinetide (ARA-290)
Outcome
No significant changePreretinal neovascularization in oxygen-induced retinopathy
Study
n: not reported in source
Oxygen-induced retinopathy (OIR)
Comparator
Control peptide
Outcome group
Vision and retina · Eye
Studied dose
1-30 μg/kgAs given in this study.
Source sentences
Summary
In OIR, pHBSP had no effect on preretinal neovascularization at any dose.
1 context sentence(design, population, supporting numbers)
Summary · context
In parallel, oxygen-induced retinopathy (OIR) was used to evaluate the effects of pHBSP on retinal ischemia and neovascularization (1-30 μg/kg pHBSP or control peptide).
Report a problemFND-2191174807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.